Dr. Behbakht is Professor and Director of the Division of Gynecologic Oncology. He is also Director of the Gynecologic Oncology fellowship. His interests are novel drug development and screening in ovarian cancer and he has led an independent and funded laboratory since 2004. In addition to his independent studies, he collaborates extensively within and outside the institution and serves on national steering committees.
Cytokeratin 5 positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer.
Bradley R. Corr, Jessica Finlay-Schultz, Rachel B. Rosen, Lubna Qamar, Miriam D. Post, Kian Behbakht, Monique A. Spillman, and Carol A. Sartorius (submitted).
Progestin Treatment Decreases CD133+ Cancer Stem Cell Populations in Endometrial Cancer.
Michael Stephen Guy, MD; Lubna Qamar, PhD; Kian Behbakht, MD; Miriam Post, MD; Jeanelle Sheeder, MSPH, PhD; Carol Sartorius, PhD; Monique Spillman, PhD (submitted)
Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers.
Goldstein CL, Susman E, Lockwood S, Medlin EE, Behbakht K.
Clin J Oncol Nurs. 2015 Apr;19(2):206-12. doi: 10.1188/15.CJON.206-212.
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H.
J Clin Oncol. 2015 Apr 1;33(10):1180-5. doi: 10.1200/JCO.2014.58.3781. Epub 2015 Feb 23.
Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery.
Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, Behbakht K, Guntupalli SR.
Obstet Gynecol. 2014 Sep;124(3):589-95. doi: 10.1097/AOG.0000000000000406.
Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.
Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR.
PLoS One. 2014 Feb 5;9(2):e86532. doi: 10.1371/journal.pone.0086532. eCollection 2014.
Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.
Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K.
Gynecol Oncol. 2012 May;125(2):451-7. doi: 10.1016/j.ygyno.2012.02.007. Epub 2012 Feb 12.
Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG.
Int J Gynecol Cancer. 2011 Nov;21(8):1422-7. doi: 10.1097/IGC.0b013e31822c7704.
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK.
Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.
Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum -II (CDDP) in a human ovarian cancer model.
Qamar L, Davis R, Anwar A, Behbakht K.
Gynecol Oncol. 2008 Sep;110(3):425-31. doi: 10.1016/j.ygyno.2008.04.039. Epub 2008 Jul 10.